Caryn Peterson

Jul 19, 2015 Board Director, Board Secretary / Treasurer

Partner, DSC Associates, LLC

San Diego, CA

Pharmaceutical Industry

Caryn Peterson has 30 years of pharmaceutical industry experience, including research and development, operations, and regulatory affairs. Currently, Ms. Peterson is a partner in Development & Strategic Consulting Associates (“DSC”), a pharmaceutical consulting firm specializing in strategic and development activities in the U.S., Asia and European Union. Prior to founding DSC, Ms. Peterson served as Vice President of Regulatory Affairs and Compliance at Ascenta Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for cancer. Prior to joining Ascenta, Ms. Peterson served 8 years as Vice President of Regulatory Affairs and Compliance at FeRx Incorporated, a drug-delivery company with a lead product under global development for primary liver cancer. As a member of executive management, she was responsible for the development and subsequent execution of a global non-clinical, clinical and regulatory strategy for the lead compound and platform drug delivery technology.

Prior to joining FeRx, Ms. Peterson was at Amylin Pharmaceuticals for 8 years where she held managerial positions in both Pharmaceutical Development and Regulatory Affairs. Prior to joining Amylin Pharmaceuticals, she was employed by Hybritech Incorporated for 9 years with increasing responsibilities in scientific positions within the Therapeutics and Diagnostics Divisions of the Company. Ms. Peterson has authored several research publications and co-inventor on multiple patents. Ms. Peterson also serves as an active member of the Scientific Advisory Board of the National Center of Drug Screening in Shanghai, China, providing significant input to the early design of global development strategies for new drug candidates discovered in China, with an emphasis on integrating both domestic and international regulatory requirements to maximize the value of discovery compounds in the partnering and/or out-licensing activities with international pharmaceutical companies.